Skip to main content

Advertisement

Table 3 Cox regression analysis of OS and PFS in 487 patients with NSCLC

From: Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement

Variable Subset OS PFS
HR (95% CI) P HR (95% CI) P
Univariate analysis
 Age ≤58 vs. >58 1.058 (0.692–1.618) 0.794 0.876 (0.685–1.121) 0.294
 Sex Male vs. female 0.710 (0.448–1.126) 0.146 1.007 (0.781–1.299) 0.958
 Histological type Adenocarcinoma vs. others 1.971 (1.200–3.235) 0.007 1.294 (0.951–1.761) 0.101
 Differentiation Well vs. poor 0.449 (0.279–0.721) 0.001 0.744 (0.576–0.961) 0.023
 Clinical stage I + II vs. III + IV 3.091 (1.855–5.149) <0.001 1.595 (1.202–2.116) 0.001
 Smoking history Non-smoker vs. smoker 1.779 (1.153–2.747) 0.009 1.100 (0.862–1.403) 0.443
 T category T1–2 vs. T3–4 2.475 (1.605–3.816) <0.001 1.582 (1.218–2.055) 0.001
 N category N0 vs. N1–3 3.155 (1.855–5.366) <0.001 1.438 (1.071–1.931) 0.016
 M category M0 vs. M1 2.275 (1.477–3.503) <0.001 1.576 (1.214–2.046) 0.001
 EGFR mutation Negative vs. positive 0.509 (0.306–0.848) 0.009 0.845 (0.647–1.102) 0.213
 ALK rearrangement Negative vs. positive 1.397 (0.740–2.635) 0.302 1.155 (0.785–1.701) 0.465
Multivariate analysis
 Histological type Adenocarcinoma vs. others 1.926 (1.102–3.364) 0.021
 T category T1–2 vs. T3–4 1.499 (1.144–1.964) 0.003
 N category N0 vs. N1–3 2.403 (1.166–4.956) 0.018
 M category M0 vs. M1 2.164 (1.292–3.624) 0.003 1.477 (1.105–1.974) 0.008
  1. OS overall survival, PFS progression-free survival, HR hazard ratio, CI confidence interval. Other footnotes as in Table 1.